Aurobindo Pharma’s subsidiary -- TheraNym Biologics (TheraNym) has signed an additional product schedule with Merck Sharpe & Dohme Singapore Trading, Singapore (MSD), which serves to further expand the existing relationship initiated pursuant to the previously disclosed arrangement in May 2024.

The aforesaid agreement pertains to the construction and commissioning of a Drug Substance manufacturing facility (Unit 2) as a greenfield project. TheraNym will invest around $150 to $175 million for establishing said facility. TheraNym Unit 2 shall encompass the installation of mammalian cell culture bioreactors with an aggregate capacity of 60,000 litres, together with requisite downstream purification infrastructure to produce Drug Substance.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.